Skip to main content

CHOP’s Food Allergy Research Highlighted Following FDA’s Approval of Palforzia

Media coverage
CHOP’s Food Allergy Research Highlighted Following FDA’s Approval of Palforzia
February 6, 2020
CHOP’s Food Allergy Research Highlighted Following FDA’s Approval of Palforzia

CHOP’s Food Allergy Research Highlighted Following FDA’s Approval of Palforzia

The U.S. Food & Drug Administration (FDA) announced the approval of PalforziaTM, a first-of-its-kind treatment for peanut allergies. Doctors and researchers from The Allergy Program at Children’s Hospital of Philadelphia (CHOP) helped test and develop the breakthrough drug.

Jonathan Spergel, MD, PhD, Section Chief of CHOP's Food Allergy Center, and Terri F. Brown-Whitehorn, MD, attending physician in the Food Allergy Center, spoke with media about the research that led up to the FDA approval and how oral immunotherapy can help children with peanut allergies.

You can see their interviews on CBS News, The Huffington Post, 6ABC, Fox29, Philly Voice, MetroKids, and Scripps National News.

Featured in this article

Specialties & Programs

Contact us

Jump back to top